Please assess the completion status of the following clinical trial:

Trial Title: Electrocautery Ablation for the Prevention of Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with ≥1 airway HGL (defined as severe dysplasia or carcinoma in situ on histology)~   PRE-REGISTRATION~   Patient has a high likelihood of having airway HGLs as evaluated by investigator:~  * patient already part of existing surveillance programme or~  * HGL identified at other hospital and patient is referred to study site or~  * patient has abnormal sputa and patient is referred to study site~   PRE-RANDOMISATION Following registration, patients undergo a baseline bronchoscopy and only those with ≥1 airway HGL(s) can continue to randomisation provided they continue to meet all the inclusion/exclusion criteria below~2. Absence of primary lung cancer as confirmed by CT thorax OR recent surgical removal of a lung cancer with clear resection margins (of cancer) confirmed OR recent successful curative SABR treatment, as confirmed by MDT~3. Male or female patients ≥18 years of age~4. No upper age limit but life expectancy thought to be at least 3 years (in the opinion of the treating clinician)~5. ECOG Performance Score 0-2~6. FEV1 ≥ 25% of predicted\*~7. DLCO/TLCO ≥ 20% of predicted (only required for registration)\*~8. Patients who are women of child-bearing potential (WOCBP) must also have a negative pregnancy test at the following time points:~   * One pregnancy test prior to registration~  * One pregnancy test within 24 hours prior to the 1st EC treatment within each EC treatment round~9. Consent to donation of biological samples for translational work. Patients will be deemed ineligible if they do not consent to donate translational samples~10. Patient is willing and able to comply to protocol procedures and attend all study visits including all bronchoscopy and EC treatment visits.~    * if spirometry is not possible (e.g. due to COVID-19) investigator assessment that the patient is sufficiently fit for bronchoscopy and EC treatment is permissible.~Exclusion criteria:~1. Finding of (micro)-invasive disease on histology (assessed at randomisation)~2. Patients who have one or more HGL present for ≥5 years which have remained persistent on white light or autofluorescence bronchoscopy (AFB) surveillance~3. Detection of active cancer or on systemic treatment for cancer, excluding basal cell skin cancers~4. Previous radiotherapy to the treatment area~5. ECOG Performance Score \>2~6. Patients who have one or more HGL greater than 3cm in length~7. Patients with a history of pulmonary hypertension~8. Patients who are anticoagulated for prosthetic heart valves~9. Decompensated heart disease with life expectancy less than 3 years~10. Severe liver and renal insufficiency with life expectancy less than 3 years~11. Patient unlikely to cooperate with a 3-year follow-up; medical or psychological condition at the discretion of the investigator which would not permit compliance with the protocol or meaningful signed informed consent~12. Participation in another study with an investigational medicinal product within one month prior to registration~13. Pregnant patients (confirmed by serum/urine ß-HCG)~14. Any other known condition which is assessed as an intolerable risk by the investigator upon inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EC treatment (Intervention Arm) (Type: EXPERIMENTAL): Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: a bronchoscopy surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
- AFB Surveillance (Control Arm) (Type: NO_INTERVENTION): Patients randomised to the surveillance (Control Arm) will have: bronchoscopy surveillance at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).

Based on this trial design, predict the completion outcome and termination type (if applicable).